VERICEL CORPORATION Cash and Cash Equivalents, Period Increase (Decrease)
VERICEL CORPORATION (VCEL) reported Cash and Cash Equivalents, Period Increase (Decrease) of $16.80 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-07.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-07
- VERICEL CORPORATION cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $16.80M, a 476.26% increase year-over-year.
- VERICEL CORPORATION cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$41.68M, a 3024.91% decline year-over-year.
- VERICEL CORPORATION cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $65.19M.
- VERICEL CORPORATION cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $2.92M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 267 month |
|---|---|---|---|---|
| 2019-03-31 | $16.80M 10-Q · filed 2019-05-07 | |||
| 2018-09-30 | -$41.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $23.51M derived: sum of 2 quarters · filed 2018-11-06 | $26.43M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $65.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $68.11M 10-Q · filed 2018-08-06 | ||
| 2018-03-31 | $2.92M 10-Q · filed 2019-05-07 | |||
| 2017-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$4.38M derived: sum of 2 quarters · filed 2018-11-06 | -$7.51M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$5.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | -$8.94M 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | -$3.13M 10-Q · filed 2018-05-08 | |||
| 2016-09-30 | -$955.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$5.70M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | -$4.75M 10-Q · filed 2017-08-09 | |||
| 2011-06-30 | -$12.73M 10-Q · filed 2011-08-15 | $18.52M 10-Q · filed 2011-08-15 | ||
| 2010-06-30 | -$620.00K 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |